TargetBeta
CDK6
cyclin dependent kinase 6 · also PLSTIRE · Cyclin dependent kinases
7 programs in company-led studies act on CDK6, from 7 companies: 2 in phase 3, 3 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| abemaciclibrule | Eli Lilly | phase 4 | 4914 running | CDK4 | NCIt |
| palbociclibrule | Pfizer | phase 4 | 364 running | CCND1, CDK4 | ChEMBL |
| trilaciclibrule | Pharmacosmos | phase 4 | 143 running | CDK4 | ChEMBL |
| culmerciclib | Sino Biopharmaceutical | phase 3 | 115 running | CDK2, CDK4 | the company's pipeline |
| flonoltinibrule | Chengdu Zenitar Biomedical Technology | phase 3 | 74 running | FLT3, JAK2 | the studies' text |
| narazaciclibrule | Hangzhou Hanx Biopharmaceuticals | phase 2 | 43 running | CDK4, NUAK1 | NCIt |
| vustanaciclib | Regor Pharmaceuticals | phase 2 | 33 running | CDK2, CDK4 | a judged reading |
Conditions their studies are in
- Breast Neoplasms, 4 programs
- Carcinoma, Non-Small-Cell Lung, 2 programs
- Sarcoma, Ewing, 2 programs
- Carcinoma, Renal Cell, 1 program
- Carcinoma, Transitional Cell, 1 program
- Colorectal Neoplasms, 1 program
- COVID-19, 1 program
- Endometrial Neoplasms, 1 program
- Glioma, 1 program
- Liposarcoma, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026abemaciclib · Eli Lilly · phase 4 · NCT07818967
- Dec 2026culmerciclib · Sino Biopharmaceutical · phase 3 · NCT05780567
- Dec 22, 2026palbociclib · Pfizer · phase 4 · NCT05468697
- Dec 30, 2026flonoltinib · Chengdu Zenitar Biomedical Technology · phase 3 · NCT07768111
- Dec 30, 2026vustanaciclib · Regor Pharmaceuticals · phase 2 · NCT06299124
- Dec 31, 2026narazaciclib · Hangzhou Hanx Biopharmaceuticals · phase 2 · NCT06703255
- Jul 15, 2027trilaciclib · Pharmacosmos · phase 4 · NCT07881705
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.